Research analysts at Guggenheim began coverage on shares of Sienna Biopharmaceuticals (NASDAQ:SNNA) in a research note issued on Tuesday. The brokerage set a “neutral” rating on the stock.

A number of other equities analysts have also commented on the stock. J P Morgan Chase & Co initiated coverage on shares of Sienna Biopharmaceuticals in a report on Monday, August 21st. They issued an “overweight” rating and a $28.00 price target on the stock. Cowen initiated coverage on shares of Sienna Biopharmaceuticals in a report on Monday, August 21st. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, BMO Capital Markets initiated coverage on shares of Sienna Biopharmaceuticals in a report on Monday, August 21st. They issued an “outperform” rating and a $30.00 price target on the stock.

Sienna Biopharmaceuticals (NASDAQ SNNA) traded down $0.32 during midday trading on Tuesday, reaching $20.53. 16,300 shares of the company’s stock traded hands, compared to its average volume of 68,436. Sienna Biopharmaceuticals has a fifty-two week low of $15.22 and a fifty-two week high of $29.25.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its earnings results on Thursday, September 7th. The company reported ($6.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($5.82). equities analysts anticipate that Sienna Biopharmaceuticals will post -2.1 earnings per share for the current fiscal year.

In related news, Director Dennis M. Fenton purchased 1,250 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were purchased at an average price of $22.96 per share, with a total value of $28,700.00. Following the acquisition, the director now directly owns 1,250 shares of the company’s stock, valued at $28,700. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Large investors have recently modified their holdings of the company. California State Teachers Retirement System bought a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth $182,000. Bank of New York Mellon Corp bought a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth $274,000. Citadel Advisors LLC bought a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth $440,000. Alyeska Investment Group L.P. bought a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth $1,133,000. Finally, TimesSquare Capital Management LLC bought a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter worth $8,571,000. 39.29% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://theolympiareport.com/2017/12/05/sienna-biopharmaceuticals-snna-coverage-initiated-at-guggenheim.html.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

Receive News & Ratings for Sienna Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.